{"id":390515,"date":"2018-12-21T00:00:00","date_gmt":"2018-12-21T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0009-2018-biopharma-renal-cell-carcinoma-disease-landscape-and-forecast-g7-2018\/"},"modified":"2026-04-15T23:24:19","modified_gmt":"2026-04-15T23:24:19","slug":"dlsfon0009-2018-biopharma-renal-cell-carcinoma-disease-landscape-and-forecast-g7-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0009-2018-biopharma-renal-cell-carcinoma-disease-landscape-and-forecast-g7-2018\/","title":{"rendered":"Renal Cell Carcinoma | Disease Landscape and Forecast | G7 | 2018"},"content":{"rendered":"<p>Although angiogenesis inhibitors are a mainstay in the treatment of renal cell carcinoma, Bristol-Myers Squibb\/Ono Pharmaceutical\u2019s\u00a0<abbr data-original-title=\"programmed cell death-1\" title=\"\">PD-1<\/abbr>\u00a0inhibitor, Opdivo, has captured significant market share\u00a0in the recurrent setting, relegating the combination of Eisai\u2019s Lenvima\/Kisplyx with Novartis\u2019s Afinitor, Pfizer\u2019s Inlyta, and single-agent\u00a0<abbr data-original-title=\"mammalian target of rapamycin\" title=\"\">mTOR<\/abbr>\u00a0inhibitors to later lines. In the first-line setting, the entry of Exelixis\/Ipsen\u2019s Cabometyx\u2014and regimens that combine immune checkpoint inhibitors with angiogenesis inhibitors\u2014look set to revolutionize the treatment of advanced disease. Following Sutent\u2019s approval for high-risk early-stage (stage I-III) patients in the United States, multiple immune checkpoint inhibitors are anticipated to launch for early-stage treatment. Despite the increasing number of agents being approved for renal cell carcinoma, the substantial unmet need that remain\u00a0means that developers of therapies that are more efficacious and\/or safer than the current standards of care could reap high commercial rewards.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>How large are the early-stage and advanced or metastatic renal cell carcinoma drug-treatable populations? Will drug-treatment rates change over time?<\/li>\n<li>How is renal cell carcinoma currently treated, and what are interviewed experts\u2019 insights on current treatment options? What clinical needs remain unfulfilled?<\/li>\n<li>Who are the key players developing combination therapies for renal cell carcinoma? How will these combination regimens be differentiated, and which look the most promising?<\/li>\n<li>Which emerging therapies\u00a0we forecast will\u00a0enter each of the renal cell carcinoma market segments? What uptake and sales are these therapies anticipated to secure?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast:<\/em>\u00a0Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><b>Markets covered:\u00a0<\/b>United States, France, Germany, Italy, Spain, United Kingdom, and Japan.<\/p>\n<p><b>Primary research:\u00a0<\/b>Twenty country-specific interviews with thought leaders (medical oncologists and urologists).<\/p>\n<p><b>Key companies:\u00a0<\/b>Bristol-Myers Squibb\/Ono Pharmaceutical, Merck &#038; Co.\/MSD, Exelixis\/Ipsen, and Pfizer.<\/p>\n<p><b>Key drugs:\u00a0<\/b>Opdivo, Keytruda, Cabometyx, and Inlyta.<\/p>\n<p><b>Population segments in market forecast:\u00a0<\/b>Early-stage (stage I-III) renal cell carcinoma, first-line advanced or metastatic renal cell carcinoma, second-line advanced or metastatic renal cell carcinoma, third-line advanced or metastatic renal cell carcinoma, and fourth-line advanced or metastatic renal cell carcinoma.<\/p>\n<p><b>Emerging therapies:\u00a0<\/b>Phase III: 7 drugs; Phase II: 20 drugs; coverage of select Phase I and preclinical products.<\/p>\n","protected":false},"template":"","class_list":["post-390515","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-renal-cell-carcinoma","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390515","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390515\/revisions"}],"predecessor-version":[{"id":576666,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390515\/revisions\/576666"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390515"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}